Ravi Anantha

Ravi Anantha's work experience includes holding the position of Director of In Vivo Testing at Bavarian Nordic starting in May 2023. From September 2018 to May 2023, they worked as the Director of In Vivo Testing at Emergent BioSolutions. Prior to that, they were a Subject Matter Expert at Universal Solutions International Inc. from November 2017 to September 2018.

Before these roles, Ravi worked at Aeras starting in 2009. Ravi served as an Associate Director from an unknown start date to December 2016, where they supervised the construction and laboratory characterization of tuberculosis (TB) vaccines. Ravi also led pre-clinical efficacy and safety testing. Ravi also worked as a Senior Scientist at Aeras from an unknown start date to 2011, leading the construction and preclinical testing of a novel bacteriophage delivery system for TB vaccines and was a member of manufacturing and formulation development teams.

Prior to Aeras, Ravi worked as a Scientist at Aeras from December 2005 to an unknown end date, where they led the construction and characterization of a bacteriophage delivery system for TB vaccines.

Ravi began their career as a Postdoctoral Fellow at The Johns Hopkins University School of Medicine from August 2004 to November 2005 and also worked as a Postdoctoral Fellow at the Naval Medical Research Center from April 2001 to August 2004.

Ravi Anantha completed their Bachelor of Arts degree in Biology at The Johns Hopkins University from 1988 to 1992. Ravi then pursued higher education and earned their PhD in Molecular Biology from the University of Maryland Baltimore, where they studied from 1993 to 2000.